Aurobindo Pharma is expanding its product portfolio in the US with high-value drugs. The portfolio mix is complemented with the introduction of high-value products and the future pipeline will include oncology, hormones, depot injections, inhalers, biosimilars, patches and films.
The addressable market for the company’s total 429 Abbreviated New Drug Applications (ANDAs) has been pegged at $91 billion, including $61 billion for the ANDAs which are under review and tentatively approved.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.